Number of Patients, Male	24
Number of Patients, Female	20
TNM Stage
IIIA	3 (6.8%)
IIIB	2 (4.5%)
IVA	14 (31.8%)
IVB	25 (56.8%)
TNM classification (Union for International Cancer Control 7th edition).
Age	Median (range): 69 years (33–82 years)
Number of Prior Systemic Therapies	Median (range): 3 (1–5)
Performance Status: ECOG	0 — 25 1 — 19 2 — 3 — Unknown —
Detailed Patient Characteristics
Age, years
<65	8 (18.2%)
≥65	36 (81.8%)
Body mass index
<25	38 (86.4%)
≥25	6 (13.6%)
RAS status
Wild‐type	25 (56.8%)
Mutant	19 (43.2%)
Prior therapy: Yes	44 (100%)
Fluoropyrimidine	44 (100%)
Oxaliplatin	44 (100%)
Irinotecan	44 (100%)
Anti‐VEGF inhibitor	44 (100%)
Anti‐EGFR antibody	25 (56.8%)
Regorafenib	9 (20.5%)
Prior number of regimens
1	1 (2.3%)
2	18 (40.9%)
3	13 (29.5%)
≥4	12 (27.3%)
Diagnosis
Colon	27 (61.4%)
Rectum	17 (38.6%)
Primary tumor locationa
Left‐sided	31 (70.5%)
Right‐sided	13 (29.5%)
Cancer Types or Histologic Subtypes	Well‐differentiated tubular adenocarcinoma (tub1), 16; moderately differentiated tubular adenocarcinoma (tub2), 26; other, 2
Abbreviations: EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.
aRight‐sided was defined as cancer that is located in the cecum, ascending colon, or transverse colon, and left‐sided as cancer located in the descending colon, sigmoid colon, or rectum.